Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: Retrospective analysis of 426 high-risk patients including ethical aspects

Archives of Gynecology and Obstetrics

Volumn 288, Issue 1, 2013, Pages 41-48

  Becker, Rolf ^a   Keller, Thomas ^b   Kiesewetter, Holger ^c   Fangerau, Heiner ^d   Bittner, Uta ^d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Acomed Statistics   (Germany)

^c Haemostaseologicum   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Adverse pregnancy outcome; ASS; Low molecular weight heparin; Preeclampsia

Indexed keywords

ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN;

ADOLESCENT; ADULT; ADVERSE PREGNANCY OUTCOME; ARTICLE; FEMALE; FETUS DEATH; FETUS DISEASE; GESTATION PERIOD; HIGH RISK PATIENT; HUMAN; INTRAUTERINE GROWTH RESTRICTION; MAJOR CLINICAL STUDY; MEDICAL ETHICS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEWBORN DEATH; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME;

EID: 84879422802     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2723-1     Document Type: Article

References (57)

1. Barton JR, Sibai BM (2008) Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 112:359-372
2. Said JM, Higgins JR, Moses EK, Walker SP, Borg AJ, Monagle PT, Brennecke SP (2010) Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol 115:5-13
3. Becker R (2011) Identification of high-risk patients for adverse pregnancy outcome based on multivariate logistic regression analysis at 20-23 gestational weeks. J Perinat Med 39:667-672
4. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD (2006) Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. Br J Obstet Gynaecol 113:580-589
5. Moldenhauer JS, Stanek J, Warschak C, Khoury J, Sibai B (2003) The frequency and severity of placental findings in women with pre-eclampsia are gestational age dependent. Am J Obstet Gynecol 189:1173-1177 (Pubitemid 37373917)
6. Campbell S, Diaz-Recasens J, Griffin DR, Cohen-Overbeek TE, Pearce JM, Willson K, Teague MJ (1983) New Doppler technique for assessing uteroplacental blood flow. Lancet 1:675-677 (Pubitemid 13158427)
7. Campbell S, Pearce MF, Hackett G, Cohen-Overbeek T, Hernandez C (1986) Q ualitative assessment of uteroplacental blood flow: early screening test for high-risk pregnancies. Obstet Gynecol 68:649-653 (Pubitemid 16005577)
8. Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH (2011) Body mass index at 11-13 week's gestation and pregnancy complications. Fetal Diag Ther 30:250-265
9. Poon LCY, Maiz N, Valencia C, Plasencia W, Nicolaides KH (2009) First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 33:23-33
10. Poon LCY, Akolekar R, Lachmann R, Beta J, Nicolaides (2010) Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 35:662-670
11. Foidart J-M, Munaut C, Chantraine F, Akolekar R, Nicolaides KH (2010) Maternal plasma soluble endoglin at 11-13 weeks gestation in pre-eclampsia. Ultrasound Obstet Gynecol 35:680-687
12. Thangaratinam S, Langenveld J, Mol BW, Khan KS (2011) Prediction and primary prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 25:419-433
13. Cuckle HS (2011) Screening for pre-eclampsia - lessons from aneuploidy screening. Placenta 32:542-548
14. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 31:66-74
15. Than NG, Romero R, Meiri H, Erez O, Xu Y, Tarquini F, Barna L, Szilagyi A, Ackerman R, Sammar M, Fule T, Karaszi K, Kovalszky I, Dong Z, Kim CJ, Zavodszky P, Papp Z, Gonen R (2011) PP13, maternal AB0 blood groups and the risk assessment of pregnancy complications. PLoS ONE 6(7):e21546. doi: 10.1371
16. North R, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC (2011) Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 342:d1875. doi: 10.1136/bmj.d1875
17. Kuc S, Wortelboer E, Van Rijn BB, Franx A, Visser GH, Schielen PCJI (2011) Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv 66:225-239
18. Infante-Rivard C, Rivard GE, Yotov WV, Génin E, Guiguet W, Weinberg C, Gauthier R, Feoli-Fonseca JC (2002) Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 347:19-25 (Pubitemid 34728953)
19. Lin J, August P (2005) Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 105:182-192 (Pubitemid 40189930)
20. Rodger MA, Paidas M, McLintock C, Middeldorp S, Kahn S, Martinelli I, Hague W, Montella KR, Greer I (2008) Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 112:320-324
21. Facco F, You W, Grobman W (2009) Genetic thrombophilias and intrauterine growth restriction. A meta-analysis. Obstet Gynecol 113:1206-1216
22. Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest J Jr, Goulet L, Lydon J, Seguin L, Dassa C, Masse A, Asselin G, Benjamin A, Miner L, Ghanem A, Kramer MS (2009) Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal preeclampsia study. Am J Obstet Gynecol 200:151.e1-9
23. Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G, Wenstrom K, Samuels P, Caritis SN, Sorokin Y, Miodovnik M, O'Sullivan M, Conway D, Wapner RJ (2010) Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 115:14-20
24. Rath W (2011) Pre-eclampsia and inherited thrombophilia: a reappraisal. Semin Thromb Hemost 37:118-124
25. Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P (1986) Low-dose Aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet 4:1-3 (Pubitemid 16182814)
26. Yu CKH, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH (2003) Randomised controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet Gynecol 22:233-239 (Pubitemid 37088545)
27. Chiaffarino F, Parazzini F, Paladini D, Acaia B, Ossola W, Marozio L, Facchinetti F, Del Giudice A (2004) A small randomised trial of low-dose aspirin in women at high risk of pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 112:142-144 (Pubitemid 38117328)
28. Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G, Uzan S, Marquis P, Paementier D, Churlet A (2003) Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the essai regional Aspirine mere-enfant study (part 1). BJOG 110:475-484 (Pubitemid 36556130)
29. Subtil D, Goeusse P, Houfflin-Debarge V, Puech F, Lequien P, Breart G, Uzan S, Quandalle F, Delcourt YM, Malek YM - ERASME collaborative group (2003) Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (part 2). BJOG 110:485-491
30. Trivedi NA (2011) A meta-analysis of low-dose aspirin for prevention of preeclampsia. J Postgrad Med 57:91-95
31. Coomarasamy A, Papaioannou S, Gee H, Khan KS (2001) Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta analysis. Obstet Gynecol 98:861-866 (Pubitemid 33042559)
32. Ruano R, Fontes RS, Zugaib M (2006) Prevention of preeclampsia with low-dose aspirin - a systematic review and meta-analysis of the main randomized controlled trials (Sao Paulo). Clinics 61:179-182
33. Askie LM, Duley L, Henderson-Smart DJ, Stewart L, on behalf of the PARIS Collaborative Group (2007) Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369:1791-1798 (Pubitemid 46782996)
34. Duley L, Henderson-Smart DJ, Meher S, King JF (2007) Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD004659. DOI: 10.1002/14651858. CD004659.pub2
35. Bujold E, Morency A-M, Roberge S, Lacasse Y, Forest J-C, Giguère Y (2009) Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can 31:818-826
36. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest J-C, Giguère Y (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy. A meta-analysis. Obstet Gynecol 116:402-414
37. Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E (2012) Early administration of low-dose Aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 31:141-146
38. Youssef A, Righetti F, Morano D, Rizzo N, Farina A (2011) Uterine artery Doppler and biochemical markers (PAPP-A, PlGF. SFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (>34 weeks) pre-eclampsia. Prenat Diagn 31:1141-1146
39. Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR, Nelson DM (2011) First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta 31:598-602
40. Odibo AO, Goetzinger KR, Odibo L, Cahill AG, Macones GA, Nelson DM, Dietzen DJ (2011) First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenat Diagn 31:990-994
41. Riyazi N, Leeda M, De Vries JIP, Huijgens PC, Van Geijn HP, Dekker GA (1998) Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 80:49-54 (Pubitemid 29272019)
42. Paidas M, Ku DH, Triche E, Lockwood C, Arkel Y (2004) Does heparin therapy improve pregnancy outcome in patients with thrombophilias? J Thromb Haemost 2:1194-1195 (Pubitemid 40186095)
43. Kupferminc MJ, Rimon E, Many A, Sharon M, Lessing JB, Gamzu R (2011) Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonatal Med 24:1042-1045
44. Kupferminc M, Rimon E, Many A, Maslovitz S, Lessing JB, Gamzu R (2011) Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Coagul Fibrinolysis 22:123-126
45. Becker R, Schmitz L, Kilavuz S, Stumm M, Wegner RD, Bittner U (2012) 'Normal' nuchal translucency: a justification to refrain from detailed scan? analysis of 6858 cases with special reference to ethical aspects. Prenat Diagn 32:550-556
46. Becker R, Vonk R, Vollert W, Entezami M (2002) Doppler sonography of uterine arteries at 20-23 weeks: risk assessment of adverse pregnancy outcome by quantification of impedance and notch. J Perinat Med 30:388-394 (Pubitemid 35252795)
47. Becker R, Vonk R (2010) Doppler sonography of uterine arteries at 20-23 weeks: depth of notch gives information on probability of adverse pregnancy outcome and degree of fetal growth restriction in a low-risk population. Fetal Diagn Ther 27:78-86
48. Voigt M, Schneider KTM, Jaehrig K (1996) Analyse des Geburtengutes des Jahrgangs 1992 der Bundesrepublik Deutschland. Geburtsh Frauenheilk 56:550-558 (Pubitemid 26371743)
49. Vainio M, Kujansuu E, Iso-Mustajärvi M, Mäenpää J (2002) Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 109:161-167 (Pubitemid 37338037)
50. Ferrazzani S, D'Alessio MC, Fatigante G, Soreca G, De Carolis S, Paradisi G, Caruso A (2006) Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens pregnancy 25:115-127 (Pubitemid 44180352)
51. Gris J-C, Chaleur C, Molinari N, Marès P, Fabbro-Peray P, Quéré I, Lefrant J-Y, Haddad B, Dauzat M (2011) Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 106:1053-1061
52. Kingdom JCP, Drewlo S (2011) Is heparin a placental anticoagulant in high-risk pregnancies? Blood 118:4780-4788
53. Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, Acaia B, Facchinett F, Battista La Sala G, Bozzo M, Rampello S, Marozio L, Diadei O, Gherardi G, Carminati S, Remuzzi G, Mannucci M for the HAPPY study group (2012) Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 119:3269-3275
54. Rodger MA (2011) Anticoagulant prophylaxis for placenta mediated pregnancy complications. Thromb Res 127(Suppl 3):S76-S80
55. American College of Obstetricians and Gynecologists: Committee on Ethics (1998) ACOG committee opinion. Ethical considerations in research involving pregnant women. Int J Gynaecol Obstet 65:93-96
56. Council for International Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO) (2002) International ethical guidelines for biomedical research involving human subjects, Geneva, pp 74-75
57. Little MO, Lyerly AD, Faden RR (2009) Pregnant women and medical research: a moral imperative. Bioethica Forum 2:61-65